HUE033191T2 - Spiro- és dispiro-l,2,4-trioxolán maláriaellenes szerek stabil adagolási formái - Google Patents

Spiro- és dispiro-l,2,4-trioxolán maláriaellenes szerek stabil adagolási formái Download PDF

Info

Publication number
HUE033191T2
HUE033191T2 HUE06744985A HUE06744985A HUE033191T2 HU E033191 T2 HUE033191 T2 HU E033191T2 HU E06744985 A HUE06744985 A HU E06744985A HU E06744985 A HUE06744985 A HU E06744985A HU E033191 T2 HUE033191 T2 HU E033191T2
Authority
HU
Hungary
Prior art keywords
sza
stable
ahol ahol
excipients
során
Prior art date
Application number
HUE06744985A
Other languages
English (en)
Inventor
Sumit Madan
Puneet Tyagi
Anupam Trehan
Vinod Kumar Arora
Harish Kumar Madan
Arno Appavoo Enose
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of HUE033191T2 publication Critical patent/HUE033191T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • C07D323/02—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (2)

  1. Bmtmúkivé^ny^mié^·: íklWbiít'öráfis, swiMf ékgolfcU fonna, amely méh»» :f*^$£s^it:ea&tt kéfggtd vegyülsz maleút sójából
    '&ί>!ώώι.ίλ 5 4 y wfNSíN'.í H OSttmffomgipMi átssydeteomotdhöl, p«limő?
    l5öl,: §y#p^S|isíl!|®:: élfbg&amp;dfi^d :pbj§bíd: Vágd: ,:|$lgyá*?3*ilag elfogadható szolvótlábbl terápiásán hatékony menny béget. <b) piperas: v!t« és u:) egy vagy jobb, gyógy assists km elfogadható segédanyagot „ óv i tzettvpoi \\ i'b Nbd s 'v i. i ís x. fo ι Λ o' i? ifor sp o' - ! t o s " íöfativ psratss'sakiss; mellett történő fotóba. során ο^λ'^-η legíessebb 5 tömegé tnodossolt anyag kdpvbdik. a, A&amp;Íki%ktypont. sminti sinlnl, sziled adagolási forma, almi a gydgy&amp;szutiltig elfogadlttifo e*c»plens tarts isnaz egyet vágy többéi a következők kösfoi kön;n;yág, hígító, gltdána'keísoafsvág, stt?zmfc?gíóns. félÜfteMktiv anyag és színezőanyag. 4 JlJ II pu'l'íi ‘Ί fo<<' V?sl,S ,dtm u HüV « >M »nt,tfo m k Okostól v v v>' tdo1”
  2. 5. Az I. Igénypont szerinti stabil, sgtíérd adsgoíási forma, ahol a segskltwiytjgok viktaft<Éit| bgÉsyőlb foS fomeg%. k Ax i, igénypont szerinti stabil, szilárd foigoiM fonna, ahol ax,,adap!áőfoms;r kifejezés oogfob::s:s foglal tóbÍe«%piÍu%;:^ntíiá^anot'és pori ?. A 6. igényps® szsrísiu stabil, i>rU|hd-:'i^^8il|8Í: torma, «6».Ι- a tabletta fslnskepső polimereket ék be? VötklédáiékiAii· tatMmaz^ egy vágy ifibb ftt«^i@e»:^^^»eiAfohlM:H»téiis bevonótéteggel van hevösv», 8, Λ 7. igénypont szerinti stabil, sztl&amp;rd adagolási fonna, ahol a bevtKióadaiők· Jutalmaz egyet vagy tbbbetakÖvetkvZííl; közÉí^dte^.gíldte'-yhgy'-.^níásszabályozó, ap&amp;iMító anyag és kenőanyag. ö. Ázk igénypon; szerinti stabil., mtdárd adagolási fonna, übot ;sv: adagolási forma a kővetkező fopésetó fosMss&amp;íö eljárással vasi eiéáíItiva: :ff (Ο) szerkezed képtebi vegyökt tnaktátaója év egy vagy több mttagr&amp;nufária ssgó#fiytg összsbevorésc. (h) a iktsvesklk gtsstistlSlása: isepgerm ídsbtkiíésbíd, te) a tp-artdlántm tus/sekeverés* így vagy több extragianaláiSi.klikisifijsiggil! ás td) a kiverek tablettává nréidése vagy kapszulába töltése jo -\r t !g<ovj>,>nt ,« sna stand, 1 /ilatvi a \seotasi fosnia oh·'! a sdaiodavs ionoi >, ovkse4o tspgss.s,* iii.it - > l Óik ö -: ól 'a" d, 'Ibi iái s.ír i..vsvi -\t' ki'kto vegyidet ntateatsbja ^ pijvrakvoi e, i\,\ i.sey mbs' insmv,mn.shisv sggüdsfoygg: össábkévfoíbse. '2:« §ή » PvMk gr»*ulátáaa h»k»ne*én«k ,Οί/ΙΛί*!''11!»'^''^^1' 'ι^ί» ιίΙι,'ίίΡΛΐ''"' |->\ ' > >JI < p) is feléli tahidtól préselése vagy kapszulába $Méss,, Ii> Mz h ig^nypooi smintt ssabü. mUxá aáap^í ..... lépésekéi XastaSixwÁ eljárással vax elMMlrv&amp;: <a> í«í utetkeztíi képdö vegyüld maisétól és pipatakvi» és egy vagy »hb gpgp&amp;Ssblág blflptólxábl segédanyag íKs*ekeveiÍ$#'éf· U'í a kiérek kö 'x^ ne«e tsHeüax<s \< ,'Λν - xgx ü^-uUm tMu- c L’ ka l íguj>iV«l vxsüxü subií v'ii.tiJ akígübv tvmus ahol ,* adasMxbM U>nm a kbu'ike'e üpséí tartalmaz* «párással van «li&amp;Hitva: vn bi! szerkó *i k-.'pkiu U'gvuk-ϊ Mwcáí'joja ev ppt'ukxüx es cj.<x χχφχ ifibb imragnirnibrh segédanyag összekeverése. lh) a keverék nedves graíídáiása nem sizes graiyjbldS>|ya|#kkgk {ν'; íi grasííiiuaiük szántása és rnvgkilfiisi tjxéreiüre redukálása, {&amp;> a granxtiauen &amp;s?eksvefése egy vagy ifibb «atig^&amp;iíul^s s§géipsyagp|:l| e i .abLuax a prev.k sa ν<κ*\ ka 'vtssikip tötn.\e V}:. Az 1. ijpsypesi várisii stabii, uibrd appüisl f#üfi, .&amp;&amp;. M llpéso'kti sarin bx aw* djérávkid eifiállbva: j> og.x x agx iobN-\gs\ xx*Xtgkt\v . b'kl g x'ü abv ibl a sygcűasxpauki:isok vríániávi, j *> vi t> i t *,os " ^Hex xv iü) xívK <ö kaka nskkPsv d\ s »v Ppérsávsiiísai és Í ;i) s keveiék labismáva préselése vagy Up5?.nbh« töltése l 1 MaNl n x> t s «v*s« ti 4ísí n*πι* «η <« \ mx »x öxbvfs *γ> veselese&amp;eo tímeso allsNa zásra, ahol a subH adagolási f>>rtna unalma* í ;í s « i i) Mx rkezeu képíetö ve^yöiat maicákéiábM terápiásait hatásos mennyiségei,
    |·»(':«>8^ a vá piperakx ink :<c) eg> vagv jobb Lk^'gbbzoíikip d(bg»(Jható segckiarsySgxst, aíxoi a hxastspixy. 40 f !;b '-..ϋί ·ν ki .·. $% söiafiv |)án«tariaií>ixi melleit idnéné iárobs során Osszaasxs fcgi'eljiífeii í k''íx;vV'-. mbUváiH! arxv-xg kxyizddik.
HUE06744985A 2005-05-18 2006-05-18 Spiro- és dispiro-l,2,4-trioxolán maláriaellenes szerek stabil adagolási formái HUE033191T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1279DE2005 2005-05-18
IN1192DE2006 2006-05-12

Publications (1)

Publication Number Publication Date
HUE033191T2 true HUE033191T2 (hu) 2017-11-28

Family

ID=37198895

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE06744985A HUE033191T2 (hu) 2005-05-18 2006-05-18 Spiro- és dispiro-l,2,4-trioxolán maláriaellenes szerek stabil adagolási formái

Country Status (9)

Country Link
US (2) US20090042821A1 (hu)
EP (1) EP1898901B1 (hu)
CN (1) CN101272777B (hu)
CY (1) CY1118583T1 (hu)
ES (1) ES2615458T3 (hu)
HU (1) HUE033191T2 (hu)
PL (1) PL1898901T3 (hu)
PT (1) PT1898901T (hu)
WO (1) WO2006123314A2 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067620B2 (en) * 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
AP2525A (en) * 2006-05-17 2012-12-05 Ranbaxy Lab Ltd Antimarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative
EP2552210B1 (en) * 2010-03-31 2017-12-20 Supernus Pharmaceuticals, Inc. Formulations of mazindol
EP2731603A1 (en) * 2011-07-14 2014-05-21 Ranbaxy Laboratories Limited Stable dosage forms of arterolane and piperaquine
WO2014132226A1 (en) * 2013-02-28 2014-09-04 Ranbaxy Laboratories Limited Stable dispersible formulation of arterolane maleate and piperaquine and process of preparation thereof
PT2976069T (pt) * 2013-03-22 2020-08-05 Adare Pharmaceuticals S R L Microcápsulas de piperaquina e composições que as contêm
WO2015140709A1 (en) * 2014-03-19 2015-09-24 Novartis Ag Solid pharmaceutical dosage forms
CN109464442B (zh) * 2018-11-19 2020-02-28 裴建梅 一种沙库巴曲缬沙坦钠药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486199B1 (en) * 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US6825230B2 (en) * 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials
US6906205B2 (en) * 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials

Also Published As

Publication number Publication date
PT1898901T (pt) 2017-02-27
CN101272777B (zh) 2013-01-30
US20090042821A1 (en) 2009-02-12
US20120183607A1 (en) 2012-07-19
EP1898901A2 (en) 2008-03-19
WO2006123314A3 (en) 2008-04-10
CN101272777A (zh) 2008-09-24
US8664265B2 (en) 2014-03-04
WO2006123314A2 (en) 2006-11-23
CY1118583T1 (el) 2017-07-12
PL1898901T3 (pl) 2017-07-31
ES2615458T3 (es) 2017-06-07
EP1898901B1 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
US8664265B2 (en) Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
HU186078B (en) Process for producing pharmaceutical compositions for peroral application containing dipyridamol
JPH11501951A (ja) プロトンポンプ抑制剤を含有するマルチプルユニットの沸騰剤形
MX2012012729A (es) Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato.
CZ280847B6 (cs) Peroorálně aplikovatelná forma léku pro léčení centrálních stavů nedostatku dopaminu
AU2012282077A1 (en) Stable dosage forms of arterolane and piperaquine
WO2010023690A2 (en) Prolonged release formulation of amisulpride
RU2536269C1 (ru) Композиция для лечения нарушений иннерваций (варианты)
WO2014104929A1 (ru) Фармацевтическая композиция для лечения вич-инфекции
EP3496719B1 (en) A multi-class anti-retroviral composition
RU2682178C2 (ru) Противотуберкулезная стабильная фармацевтическая композиция в форме таблетки с покрытием, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
WO2008029351A2 (en) A modified release formulation comprising amoxicillin and clavulanate
KR20200015758A (ko) 제약 조성물
RU2188018C2 (ru) Композиционный состав антибактериального лекарственного средства
US20120121722A1 (en) Atazanavir formulations
EP3335701A1 (en) Pharmaceutical composition comprising omarigliptin
OA16845A (en) Stable dosage forms of arterolane and piperaquine
WO2024084496A1 (en) Pharmaceutical compositions comprising acalabrutinib maleate
KR20180002437A (ko) 독실아민 및 피리독신을 포함하는 약제학적 복합 제제
WO2015150948A1 (en) Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
KR20160034982A (ko) 이소니아지드 과립 및 리파펜틴 과립을 포함하는 코팅정 형태의 안정한 항결핵성 제약 조성물 및 그의 제조 방법